Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Net Income towards Common Stockholders (2023 - 2025)

Contineum Therapeutics has reported Net Income towards Common Stockholders over the past 3 years, most recently at -$15.1 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$15.1 million for Q4 2025, down 3.71% from a year ago — trailing twelve months through Dec 2025 was -$59.9 million (down 41.81% YoY), and the annual figure for FY2025 was -$59.8 million, down 41.54%.
  • Net Income towards Common Stockholders for Q4 2025 was -$15.1 million at Contineum Therapeutics, down from -$12.8 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for CTNM hit a ceiling of $41.6 million in Q2 2023 and a floor of -$16.0 million in Q2 2025.
  • Median Net Income towards Common Stockholders over the past 3 years was -$9.6 million (2024), compared with a mean of -$6.6 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 121.68% in 2024 and later decreased 3.71% in 2025.
  • Contineum Therapeutics' Net Income towards Common Stockholders stood at -$7.8 million in 2023, then crashed by 87.21% to -$14.6 million in 2024, then dropped by 3.71% to -$15.1 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$15.1 million (Q4 2025), -$12.8 million (Q3 2025), and -$16.0 million (Q2 2025) per Business Quant data.